IBI311
Snapshot
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
IBI311 is a monoclonal antibody that targets IGF-1R and is being developed for thyroid eye disease. It is in a Phase III clinical trial as of 2023.
IBI311 is a monoclonal antibody that targets IGF-1R and is being developed for thyroid eye disease. It is in a Phase III clinical trial as of 2023.
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1251211632 under CC BY-SA 4.0; modifications have been made.